Abstract:Respiratory viral infections (VRTIs) rank among the leading causes of global morbidity and mortality, affecting millions of individuals each year across all age groups. These infections are caused by various pathogens, including rhinoviruses (RVs), adenoviruses (AdVs), and coronaviruses (CoVs), which are particularly prevalent during colder seasons. Although many VRTIs are self-limiting, their frequent recurrence and potential for severe health complications highlight the critical need for effective therapeutic strategies. Viral proteases are crucial for the maturation and replication of viruses, making them promising therapeutic targets. This review explores the pivotal role of viral proteases in the lifecycle of respiratory viruses and the development of protease inhibitors as a strategic response to these infections. Recent advances in antiviral therapy have highlighted the effectiveness of protease inhibitors in curtailing the spread and severity of viral diseases, especially during the ongoing COVID-19 pandemic. It also assesses the current efforts aimed at identifying and developing inhibitors targeting key proteases from major respiratory viruses, including human RVs, AdVs, and (severe acute respiratory syndrome coronavirus-2) SARS-CoV-2. Despite the recent identification of SARS-CoV-2, within the last five years, the scientific community has devoted considerable time and resources to investigate existing drugs and develop new inhibitors targeting the virus's main protease. However, research efforts in identifying inhibitors of the proteases of RVs and AdVs are limited. Therefore, herein, it is proposed to utilize this knowledge to develop new inhibitors for the proteases of other viruses affecting the respiratory tract or to develop dual inhibitors. Finally, by detailing the mechanisms of action and therapeutic potentials of these inhibitors, this review aims to demonstrate their significant role in transforming the management of respiratory viral diseases and to offer insights into future research directions.

Antiviral agents and therapeutics against respiratory viruses

Current antiviral agents against human adenoviruses associated with respiratory infections

Antivirals for Respiratory Viral Infections: Problems and Prospects.

Antivirals for Respiratory Viral Infections: Problems and Prospects

Antiviral Drugs in the Treatment of Respiratory Virus Infections

Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins

Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections

Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies

The need for new antiviral agents

Respiratory viruses: Preventive and therapeutic approaches to diverse pathogens

Anno 2021: Which antivirals for the coming decade?

Intranasal antivirals against respiratory syncytial virus: the current therapeutic development landscape

Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell

Nucleosides for the treatment of respiratory RNA virus infections

Protease Inhibitors as Game Changers in Respiratory Viruses Management

Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics

Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies

Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus

Recent Advances in Novel Antiviral Therapies against Human Adenovirus

Viral Infectious Disease and Natural Products with Antiviral Activity.

Vaccines for Respiratory Viruses—COVID and Beyond